Tillkännagivande • Nov 28
EC Healthcare Declares No Dividend for the Six Months Ended September 20, 2025 EC Healthcare declared no dividend for the six months ended September 20, 2025 (2024: 1.0 HK Cents). Tillkännagivande • Nov 17
EC Healthcare to Report First Half, 2026 Results on Nov 28, 2025 EC Healthcare announced that they will report first half, 2026 results on Nov 28, 2025 Tillkännagivande • Jun 23
EC Healthcare Announces Appointment of Member of the Nomination Committee The board of directors of EC Healthcare announced that Mrs. Leung Yang, Shih Ti Marianne, a non-executive director of the Company and Mr. Ma Ching Nam, an independent non-executive director of the Company, have been appointed as the members of the nomination committee under the Company with effect from 23 June 2025. Tillkännagivande • Jun 19
EC Healthcare, Annual General Meeting, Aug 22, 2025 EC Healthcare, Annual General Meeting, Aug 22, 2025. Tillkännagivande • Jun 09
EC Healthcare to Report Fiscal Year 2025 Results on Jun 19, 2025 EC Healthcare announced that they will report fiscal year 2025 results on Jun 19, 2025 Tillkännagivande • Nov 28
EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025 EC Healthcare declared Ordinary interim (semi-annual) dividend for the six months ended 30 September 2024 of HKD 0.01 per share. The dividend will be payable on 24 January 2025 with record date of 07 January 2025 and Ex-dividend date of 30 December 2024. Tillkännagivande • Nov 09
EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024 EC Healthcare announced that they will report first half, 2025 results on Nov 28, 2024 Tillkännagivande • Nov 08
Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024 EC Healthcare provided sales expectations for Six months ended 30 September 2024. For the six months, The Group expects to record overall Sales Volume of no less than HKD 2,100 million for the Period, representing a decrease of no more than 4% as compared with the same period last year. Tillkännagivande • Aug 16
EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024 EC Healthcare provided group earnings guidance for the period from 1 April 2024 to 30 June 2024. For the quarter, the company expects overall Sales Volume of no less than HKD 1,040 million for the Quarter, representing a decrease of no more than 4% as compared with the same quarter last year. Tillkännagivande • Jun 28
EC Healthcare, Annual General Meeting, Aug 23, 2024 EC Healthcare, Annual General Meeting, Aug 23, 2024. Tillkännagivande • Jun 15
EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024 EC Healthcare announced that they will report fiscal year 2024 results on Jun 27, 2024 Tillkännagivande • Jun 14
An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million. An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million on June 12, 2024. Tillkännagivande • Dec 08
EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023 The board of directors of EC Healthcare announced that, Mr. Wong Chi Cheung has tendered his resignation as executive director and chief digital officer of the Company with effect from 31 December 2023 due to other work commitments. Mr. Wong has confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Tillkännagivande • Dec 01
EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024 EC Healthcare declared an interim dividend of HKD 0.005 per share for the six months ended 30 September 2023. The dividend payable on January 19, 2024 to the shareholders recorded on 05 January 2024 and the Ex-dividend date is 28 December 2023. Tillkännagivande • Nov 18
Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023 EC Healthcare provided earnings guidance for the six months ended 30 September 2023. For the period, the company expects a decrease of not more than 80% in profit after tax ("Net Profit") for the Reporting Period as compared with the Net Profit of approximately HKD 105.2 million for the corresponding period ended 30 September 2022. However, if comparing to the second half of financial year ended 31 March 2023, it is expected that the financial results of the Group may record: an increase of not less than 1,000% in Net Profit for the Reporting Period as compared with the Net Profit of approximately HKD 1.8 million for six months ended 31 March 2023. The Board believes that such year-on-year decrease in Net Profit during the Reporting Period was mainly attributable to: the decrease of approximately HKD 43.4 million in subsidies from Hong Kong Government under the Employment Support Scheme; temporary low operation leverage of the newly established service points from the previous financial year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from the organic expansion during the previous financial year ended 31 March 2023; and the increase in interest expenses from bank borrowings of approximately HKD 17.0 million due the increasing interest rate. Tillkännagivande • Nov 17
EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023 EC Healthcare announced that they will report first half, 2024 results on Nov 30, 2023 Tillkännagivande • Nov 02
EC Healthcare Announces Executive Changes EC Healthcare Announced that Mr. Tang Chi Fai Eddy has resigned as chief executive officer of the Company with effect from 1 November 2023 due to the wish to enable the Company to fully comply with code provision C.2.1 of the Corporate Governance Code of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which states that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as chief executive officer of the Company that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the holders of securities of the Company. Mr. Tang will continue to be the Chairman of the Board and an executive Director. Mr. Lu Lyn Wade Leslie, an executive director and the co-chief executive officer of the Company, is re-designated as the chief executive officer of the Company with effect from 1 November 2023. Mr. Lu, aged 44, joined the Group in August 2021 and is an executive director and was the co-chief executive officer of the Company. He focuses on Group's high level strategy, systems building, implementation and cultural alignment. Mr. Lu is a seasoned corporate executive with 22 years of management experience across multiple industry verticals. Mr. Lu worked in Sun Hung Kai Real Estate Agency Limited as Deputy Chief Digital Officer. Before that, Mr. Lu was an executive at Cathay Pacific Airways Limited during 2001-2007 & 2008-2020. His roles include General Manager Digital, General Manager Product, managerial positions in airline planning, cargo, flight operations, customer relationship management as well as oversea station at Thailand, Vietnam and United States. Mr. Lu graduated from The Hong Kong University of Science and Technology ("HKUST") with a Bachelor's degree in Civil Engineering in 2001 and a master's degree in Global Finance in 2009 from New York University and HKUST. Mr. Lu has entered into a service agreement with the Company on 23 August 2021 as an executive director and the co-chief executive officer of the Company for a term of 3 years commencing on 23 August 2021. A supplemental agreement has been entered into between Mr. Lu and the Company on 1 November 2023, pursuant to which Mr. Lu is re-designated as chief executive officer of the Company. Pursuant to the service agreement (as amended), the remuneration of Mr. Lu shall remain unchanged at HKD 400,000 per month plus other discretionary bonus and share options as may be determined by the Board and other terms of appointment shall also remain unchanged. His remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the salaries paid by comparable companies, time commitment, duties and responsibilities of Mr. Lu, the Company's performance and profitability, the remuneration policy and prevailing market rate. As at the date of this announcement, Mr. Lu holds 10,000,000 share options in the Company. Tillkännagivande • Sep 02
Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023 EC Healthcare on 23 August 2023 approved dividend of HKD 0.042 per share for the year ended 31 March 2023. Record date is 05 September 2023. Payment date is 18 September 2023. Ex-dividend date is 04 September 2023. Tillkännagivande • Aug 24
Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023 EC Healthcare at its annual general meeting held on 23 August 2023 approved final dividend of HKD 0.042 per share for the year ended 31 March 2023. Tillkännagivande • Jun 20
EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023 EC Healthcare provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, company expects a decrease of not more than 61% in profit after tax, a decrease of not more than 20% in EBITDA. Tillkännagivande • Jun 13
EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023 EC Healthcare announced that they will report fiscal year 2023 final results on Jun 23, 2023 
